Evidence map›Paper›PMID 26557934›Full record

ArticlePrzeglad gastroenterologiczny2015

New pharmaceuticals in inflammatory bowel disease.

Michał Łodyga, Piotr Eder, Witold Bartnik, Maciej Gonciarz, Maria Kłopocka, Krzysztof Linke, Ewa Małecka-Panas, Piotr Radwan, Grażyna Rydzewska

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Przeglad gastroenterologiczny, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Assessment of the effectiveness of Budesonide MMXPrzeglad gastroenterologiczny · 2023
    Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Michał ŁodygaDepartment of Internal Medicine and Gastroenterology with IBD Subdivision, Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland.
Piotr EderDepartment of Gastroenterology, Human Nutrition and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.
Witold BartnikDepartment of Gastroenterology and Hepatology, Medical Centre for Postgraduate Education, Warsaw, Poland.
Maciej GonciarzDepartment of Gastroenterology, St. Barbara Provincial Specialist Hospital, Sosnowiec, Poland.
Maria KłopockaGastroenterology Nursing Unit, Centre for Therapeutic Endoscopy, University Hospital No 2, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
Krzysztof LinkeDepartment of Gastroenterology, Human Nutrition and Internal Diseases, Poznan University of Medical Sciences, Poznan, Poland.
Ewa Małecka-PanasDepartment of Gastrointestinal Tract Diseases, Medical University of Lodz, Lodz, Poland.
Piotr RadwanDepartment Gastroenterology and Endoscopy, Medical University of Lublin, Lublin, Poland.
Grażyna RydzewskaDepartment of Internal Medicine and Gastroenterology with IBD Subdivision, Central Clinical Hospital of the Ministry of the Interior, Warsaw, Poland ; Faculty of Health Sciences, Jan Kochanowski University, Kielce, Poland.
Poznan University of Medical Sciences · PLCentral Clinical Hospital · PLCollegium Medicum in Bydgoszcz · PLJan Kochanowski University · PLMedical University of Lodz · PLMedical University of Lublin · PLPostgraduate School of Molecular Medicine · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper complements the previously published Guidelines of the Working Group of the Polish Society of Gastroenterology and former National Consultant in Gastroenterology regarding the management of patients with Crohn's disease and ulcerative colitis. Attention was focused on the new pharmaceutical recently registered for inflammatory bowel disease treatment.

Indexed as

budesonide MMXCrohn's diseasegolimumabulcerative colitisvedolizumab

Identifiers

PMID26557934
PMCPMC4631272
OpenAlexW2419588640

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.